Arja Kaipainen

Rockefeller University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

47h-index14.8kcitations94works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(25), Prostate Cancer Treatment and Research(23), Lymphatic System and Diseases(14), Protein Degradation and Inhibitors(14), Cancer, Lipids, and Metabolism(13)

Publications94 total

Addendum: Resolvins suppress tumor growth and enhance cancer therapy
The Journal of Experimental Medicine·2024· 3 citedOpen Access
Figure S3 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
2023Open Access
Figure S4 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
2023Open Access
Figure S3 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
2023Open Access
Data from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
2023Open Access
Supplementary Data from Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer
2023Open Access
Figure S2 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
2023Open Access
Figure S5 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
2023Open Access
Data from Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer
2023Open Access
Figure S1 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
2023Open Access
Figure S1 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
2023Open Access
Figure S5 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
2023Open Access
Supplementary Data from Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer
2023Open Access
Figure S4 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
2023Open Access
Data from Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer
2023Open Access
Data from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
2023Open Access
Figure S2 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
2023Open Access
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
Nature Communications·2021· 161 citedOpen Access
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice
UNC Libraries·2020Open Access
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
2020· 21 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Kari Alitalo(18), Dipak Panigrahy(12), Catherine Butterfield(10), Mark W. Kieran(10), Judah Folkman(9), Sui Huang(9), Vladimir Joukov(6), Peter S. Nelson(6), Katri Pajusola(5), Ilsa M. Coleman(5), Eva Corey(5), Colm Morrissey(5), Athina Lymboussaki(5), Emy J. Chen(5), Diane R. Bielenberg(5), Giorgio Pietramaggiori(5), Jared M. Lucas(4), Lisha G. Brown(4), Holly M. Nguyen(4), Lawrence D. True(4)